ClinicalTrials.gg
Active, not recruitingNCT01941641Updated Nov 17, 2025

Colon Neoadjuvant FOLFOXIRI Study

A Phase 2 interventional study of neoadjuvant FOLFOXIRI and Capecitabine in Rectal Cancer, sponsored by Chinese University of Hong Kong. Active, not recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Chinese University of Hong Kong · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies testing capecitabine in Rectal Neoplasms — 18 open to participants now, 28 under way, 4 of them phase 3. Capecitabine · Rectal Neoplasms.

Planned enrollment
74th of 130
40 · median 49
Started
2013
with 3 others
Phase 2
85 of 136
13 open now
Primary completion
2026-12
later than 19 of 27 live
Registered
86th of 136
by date

Among the 136 studies testing capecitabine in Rectal Neoplasms, this one is the 74th largest by planned enrollment of the 130 interventional ones that give a count, is one of 4 that started in 2013, is one of 85 in phase 2, reaches primary completion later than 19 of the 27 other live ones, and was the 86th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

18 of the 136 studies testing capecitabine in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing capecitabine in Rectal Neoplasms, or all of them as a file.
02

Study summary

Objective tumour response rate to FOLFOXIRI to pre-operative therapy.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years of either sex.
  • performance status 0-1
  • by 1.1 criteria.
  • confirmed rectal adenocarcinoma (defined as either mid- or low rectal cancer that is located within 12 cm from the anal verge OR below the peritoneal reflection) that is previously untreated.
  • 'High risk' rectal cancer, or rectal cancers that are considered marginally operable where there is a significant risk of positive surgical margin:

    • T3 (low-lying tumour at or below the levators) or T4, or
    • Tumour infiltrating perirectal fat, or
    • Any T-stage (T1-4) and node-positive tumour (invading surrounding structures or peritoneum)
  • Adequate bone marrow, renal and hepatic function as defined by: >= 1.5 x 109/L, >= 9 g/L, >= 100 x 109/L, calculated >= 55 ml/min, total =\<1.5 x the , (ALT) =\<2.5 upper limit of normal.

Exclusion criteria

Exclusion Criteria:

  • Known distant , even if the metastasis has been resected.
  • History of another invasive within the last 5 years, except for treated basal cell carcinoma of the skin, cervical intraepithelial neoplasia, or non-invasive DCIS of the breast.
  • Upper rectal cancer that is located above the peritoneal reflection.
  • Primary tumour associated with any one of the following features:

    • Frank intestinal obstruction, or
    • Endoscope unable to pass through the tumour's lumen plus worsening local obstructive symptoms. Note: Patients with such features should be assessed by the surgical team regarding stomal bypass prior to study enrolment. Such patients can still be considered for study enrolment after undergoing stomal bypass.
  • Known reaction to the study drugs (i.e. fluoropyrimidine, irinotecan, oxaliplatin)
  • Known peripheral neuropathy of grade 2 or more in severity.
  • Patients who have received an experimental anticancer therapy within the last 28 days.
  • Previous pelvic radiotherapy. Previous oxaliplatin or irinotecan for the treatment of colon or rectal cancer
  • Patient with hip prosthesis
  • Major surgery within the last 28 days. Exception: Any patient who underwent stomal bypass for obstructing primary tumour within the last 14 days are still eligible, as long as the patient has sufficiently recovered from the surgery at the investigator's discretion.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    neoadjuvant FOLFOXIRI

    Drug: neoadjuvant FOLFOXIRI · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Objective tumour response rate

    Time frame: 2 years

Secondary outcomes

  1. Tumour regression grade

    Time frame: 2 years

  2. pathologic complete response

    Time frame: 2 years

  3. Rate of circumferential resection margin (CRM) clearance

    Time frame: 2 years

  4. Rate of tumour downstaging

    Time frame: 2 years

  5. Number of Participants with Adverse Events

    Time frame: 2 years

  6. Overall survival

    Time frame: 5 years

  7. disease-free survival, relapse-free survival

    Time frame: 5 years

  8. Time to local (and distant) recurrence

    Time frame: 5 years

  9. Number of patients with 30-day post-operative mortality

    Time frame: 1 month

  10. Compliance to study treatment

    Time frame: 2 years

  11. Number of response to neoadjuvant therapy

    Time frame: 2 years

07

Study locations

1 site
  • Department of Clinical Oncology
    Hong Kong, Hong Kong
08

References and documents

Publications

  • Lui RN, Chu S, Ng DCK, Li L, Cho CCM, Hung EHY, Wong KH, Mo FKF, Wong ECH, Hui CWC, Lam DCM, Suen J, Kang W, Ho WM, Futaba K, Hon SSF, Yan K, Ng SSM, Ma BBY. Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer. Oncologist. 2026 May 8;31(6):oyag162. doi: 10.1093/oncolo/oyag162. PubMed 42050144 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2013 (actual). Primary completion is estimated for Dec 2026, 158 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 158 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2013
First posted
Sep 13, 2013
StartActual
Oct 9, 2013
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01941641
Responsible party
CCTU (Comprehensive Cancer Trials Unit, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 13, 2013
Start date
Oct 9, 2013
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Brigette MA, MD, FRCP
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion